Feb 15 2021 Read 275 Times
In recent years, nanomedicine has proven to be key in overcoming many of the challenges associated with poorly water-soluble drugs. Decreasing the size of drug particles can increase bioavailability and solubility, as a result of the increased API surface area.
Due to increased bioavailability, a lower amount of API is required, which in turn leads to a more cost-efficient product, with less risks and side effects for the patient [1].
High pressure homogenisation has long been the favoured method of particle size reduction and is often considered as a first-generation approach. Recently, second-generation approaches have been introduced and these involve a combination of technologies (SmartCrystal processes). One of which is known as the H96 process -the combination of freeze drying, followed by high pressure homogenisation.